Evelina London Children’s Hospital

Palforzia Shows Positive Results in Peanut-Allergic Children Ages 1-3 in Phase...

News Wire ~ 3rd Party Press Release - 2023/11/20

73.5% of patients treated with PALFORZIA tolerated a 600 mg single dose of peanut protein at 12 months.

Positive Results from Phase 3 Study of PALFORZIA® in Peanut-Allergic Children...

News Wire ~ 3rd Party Press Release - 2022/11/11

73.5% of patients treated met the primary outcome at 12 months compared with 6.3% of patients in the placebo arm.

Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of service and Privacy Policy.

SnackSafely.com, PO Box 141, Hillsdale, NJ 07642

Tag: Evelina London Children’s Hospital

Palforzia Shows Positive Results in Peanut-Allergic Children Ages 1-3 in Phase...

Positive Results from Phase 3 Study of PALFORZIA® in Peanut-Allergic Children...